Newsroom | 38202 results

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced the presentation of new data from its CATALYST and MOMENTUM trials at the American Diabetes Association’s 86th Scientific Sessions. The presentations underscore the critical role of...

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that it will participate in the Goldman Sachs 47th Annual Global Healthcare Conference. Tempus Founder and CEO Eric Lefkofsky will participate in a fireside chat at 2:00 p.m. ET on Monday, June 8. A live webcast of the conversation will be available here. About Tempus Tempus is a technology company advancing precision medicine through the practi...

MANHASSET, N.Y.--(BUSINESS WIRE)--John M. Kane, MD, co-director of the Institute of Behavioral Science at Northwell Health’s Feinstein Institutes for Medical Research, was awarded the 2026 Lifetime Achievement Award from the Schizophrenia International Research Society (SIRS). This recognition celebrates his decades-long contributions that have transformed the understanding, treatment and outcomes for individuals living with schizophrenia worldwide. The SIRS Lifetime Achievement Award is one of...

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera Appoints Dr. Victor Sandor to its Board of Directors...

TURÍN, Italia--(BUSINESS WIRE)--Reply [EXM, STAR: REY] y el Instituto Europeo de Oncología (IEO) han puesto en marcha una colaboración centrada en el desarrollo conjunto y el entrenamiento de modelos de lenguaje a gran escala específicos para el ámbito de la oncología. La iniciativa aúna la experiencia de Reply en la creación de modelos generativos de vanguardia basados en el conocimiento empresarial con la experiencia clínica y los activos de datos del IEO, con el fin de desarrollar modelos ad...

TURIN, Italie--(BUSINESS WIRE)--Reply [EXM, STAR : REY] et l’Institut européen d’oncologie (IEO) ont lancé une collaboration axée sur le codéveloppement et l’entraînement de modèles linguistiques de grande envergure spécialisés en oncologie. Cette initiative associe l’expertise de Reply en matière de création de modèles génératifs de pointe fondés sur les connaissances de l’entreprise à l’expertise clinique et aux ressources de données de l’IEO afin de développer des modèles adaptés aux context...

TURIJN, Italië--(BUSINESS WIRE)--Reply [EXM, STAR: REY] en het European Institute of Oncology (IEO) zijn een samenwerking aangegaan die is gericht op de gezamenlijke ontwikkeling en training van domeinspecifieke grote taalmodellen voor de oncologie. Het initiatief combineert de expertise van Reply in het bouwen van geavanceerde generatieve modellen op basis van bedrijfskennis met de klinische expertise en data-assets van het IEO. Ze zullen modellen ontwikkelen die inspelen op de zeer complexe o...

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that it will participate in and present at the 47th Annual Goldman Sachs Global Healthcare Conference in Miami, Florida on Monday, June 8, 2026. Members of the Summit management team will participate in a fireside chat presentation at 10:00 AM ET, providing a corporate overview and update on recent progress, including the development of its innovative investigational bispecific antibody, ivonescimab. The presentatio...

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on June 1, 2026, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 353,000 shares of common stock to twenty new employees under the Company’s 2024 Induc...

BOSTON--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that, effective on June 1, 2026, the Compensation Committee of Sensei’s Board of Directors granted three new employees options to purchase an aggregate of 19,300 shares of the Company’s common stock in connection with their employment (collectively, the “Option Awards”). The Option Awards were granted pursuant to the Company’s 2026 Inducement Plan as a material inducement to the individuals entering employment...